J 2023

New findings on the action of hypericin in hypoxic cancer cells with a focus on the modulation of side population cells

BUĽKOVÁ, Viktória, Jana VARGOVÁ, Marián BABINČÁK, Rastislav JENDŽELOVSKÝ, Zbyněk ZDRÁHAL et. al.

Základní údaje

Originální název

New findings on the action of hypericin in hypoxic cancer cells with a focus on the modulation of side population cells

Autoři

BUĽKOVÁ, Viktória (703 Slovensko), Jana VARGOVÁ (703 Slovensko), Marián BABINČÁK (703 Slovensko), Rastislav JENDŽELOVSKÝ (703 Slovensko), Zbyněk ZDRÁHAL (203 Česká republika, garant, domácí), Pavel ROUDNICKÝ (203 Česká republika, domácí), Ján KOŠUTH a Peter FEDOROČKO

Vydání

Biomedicine and Pharmacotherapy, Elsevier, 2023, 0753-3322

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30104 Pharmacology and pharmacy

Stát vydavatele

Francie

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 7.500 v roce 2022

Kód RIV

RIV/00216224:14740/23:00131566

Organizační jednotka

Středoevropský technologický institut

UT WoS

000998460000001

Klíčová slova anglicky

Hypericin; Hypoxia; Breast cancer resistance protein; Side population; ECM reorganization; Proteomics

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 9. 10. 2024 13:27, Ing. Martina Blahová

Anotace

V originále

The presence of key hypoxia regulators, namely, hypoxia-inducible factor (HIF)-1 alpha or HIF-2 alpha, in tumors is associated with poor patient prognosis. Hypoxia massively activates several genes, including the one encoding the BCRP transporter that proffers multidrug resistance to cancer cells through the xenobiotic efflux and is a determinant of the side population (SP) associated with cancer stem-like phenotypes. As natural medicine comes to the fore, it is instinctive to look for natural agents possessing powerful features against cancer resistance. Hypericin, a pleiotropic agent found in Hypericum plants, is a good example as it is a BCRP substrate and po-tential inhibitor, and an SP and HIF modulator. Here, we showed that hypericin efficiently accumulated in hypoxic cancer cells, degraded HIF-1/2 alpha, and decreased BCRP efflux together with hypoxia, thus diminishing the SP population. On the contrary, this seemingly favorable result was accompanied by the stimulated migration of this minor population that preserved the SP phenotype. Because hypoxia unexpectedly decreased the BCRP level and SP fraction, we compared the SP and non-SP proteomes and their changes under hypoxia in the A549 cell line. We identified differences among protein groups connected to the epithelial-mesenchymal transition, although major changes were related to hypoxia, as the upregulation of many proteins, including serpin E1, PLOD2 and LOXL2, that ultimately contribute to the initiation of the metastatic cascade was detected. Alto-gether, this study helps in clarifying the innate and hypoxia-triggered resistance of cancer cells and highlights the ambivalent role of natural agents in the biology of these cells.

Návaznosti

823839, interní kód MU
Název: European Proteomics Infrastructure Consortium providing Access (Akronym: EPIC-XS)
Investor: Evropská unie, European Proteomics Infrastructure Consortium providing Access, RI Research Infrastructures (Excellent Science)
90242, velká výzkumná infrastruktura
Název: CIISB III